Long Pulse 1064 nm Nd:YAG Laser in the Treatment of Erythematotelangiectatic Rosacea and Other Erythematous Telangiectatic Facial Conditions

NCT06908915 | Completed

• 1 other identifier: KHCMS: 12/241-2023
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical study is to assess the effectiveness of Nd:YAG laser 1064 nm in the long pulse mode in the treatment of signs of rosacea including the erythema of the face and telangiectasia. The used parameter of this laser was of very low energy (spot size: 5mm, fluence: 4.07 J/Cm2, energy: 800 millijoules (mJ) and frequency: 5 Hz. About 2-3 passes performed in each treatment session. Up to four sessions were performed for each patient with 2 weeks interval) and also its was expected to have minimal adverse effects.

Conditions

Rosacea, Erythematotelangiectatic

Keywords

Nd:YAG laser

Outcome Measures

Primary Outcomes (1)

• Changes in erythema of face of patients with rosacea been treated by ND:YAG laser 1064 nm long pulse width by using clinician erythema scale (CEA)

  Erythema was graded from 0 to 4 using clinician erythema assessment scale (CEA). The score 0 is the lowest score of erythema and score 4 means the highest severity of erythema of the skin

  Three months

Study Arms (1)

Definition: rosacea patients. Limit: 30 patients

EXPERIMENTAL

Patients with rosacea received treatment with Nd:YAG laser with spot size: 5mm, fluence: 4.07 J/Cm2, energy: 800 mJ and frequency: 5 Hz. About 2-3 passes performed in each treatment session. Up to four sessions were performed for each patient with 2 weeks interval

Device: Nd:YAG laser 1064 nm

Interventions

Nd:YAG laser 1064 nm DEVICE

The entire face of each patient with rosacea was treated with long-pulse 1064nm Nd:YAG laser. The parameters that been used were spot size: 5mm, fluence: 4.07 J/Cm2, energy: 800 mJ and frequency: 5 Hz. About 2-3 passes performed in each treatment session. Up to four sessions were performed for each patient with 2 weeks interval.

Definition: rosacea patients. Limit: 30 patients

Eligibility Criteria

• Age: 32 Years - 52 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Patient with rosacea (erythemato-telangiectatic type)

You may not qualify if:

• Other clinical types of rosacea
• Pregnancy and lactation in females
• History of malignancies
• History of photosensitivity
• History of any other modalities of treatment of rosacea over last 6 months

Sponsors & Collaborators

• Hawler Medical University: lead

Study Sites (1)

Hawler Medical University

Erbil, 44001, Iraq

Location

MeSH Terms

Conditions

Rosacea

Condition Hierarchy (Ancestors)

Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Asst Professor

Study Record Dates

• First Submitted: December 28, 2024
• First Posted: April 3, 2025
• Study Start: March 3, 2023
• Primary Completion: November 1, 2023
• Study Completion: November 4, 2024
• Last Updated: April 3, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will share

Locations

IR (1)